A phase IV, open-label, single centre, single-arm, pilot study to assess Cerebrospinal fluid INflammatory markers after Addition of Maraviroc to MONotherapy darunavir/ritonavir - The CINAMMON Study SSAT046

Trial Profile

A phase IV, open-label, single centre, single-arm, pilot study to assess Cerebrospinal fluid INflammatory markers after Addition of Maraviroc to MONotherapy darunavir/ritonavir - The CINAMMON Study SSAT046

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Maraviroc (Primary) ; Darunavir/ritonavir
  • Indications HIV-1 infections
  • Focus Biomarker; Pharmacodynamics
  • Acronyms CINAMMON
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2017 Results assessing effect of Maraviroc on CSF inflammatory markers, presented at the 24th Conference on Retroviruses and Opportunistic Infections
    • 26 Feb 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top